149 related articles for article (PubMed ID: 7517251)
1. Evaluation of CYFRA 21-1 as a new marker for non-small cell lung cancer.
Niklinski J; Furman M; Chyczewska E; Chyczewski L; Rogowski F; Jaroszewicz E; Laudanski J
Eur J Cancer Prev; 1994 Mar; 3(2):227-30. PubMed ID: 7517251
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
3. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
[TBL] [Abstract][Full Text] [Related]
4. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
5. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group.
Rastel D; Ramaioli A; Cornillie F; Thirion B
Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651
[TBL] [Abstract][Full Text] [Related]
6. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
[TBL] [Abstract][Full Text] [Related]
8. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer.
Niklinski J; Furman M; Laudanski J; Kozlowski M
Eur J Cancer Prev; 1992 Oct; 1(6):401-6. PubMed ID: 1334443
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
[TBL] [Abstract][Full Text] [Related]
12. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
13. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers].
Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB
Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432
[TBL] [Abstract][Full Text] [Related]
14. [Cyfra 21-1 new marker for non-small cell lung cancer].
Nikliński J; Furman M; Chyczewski L; Chyczewska E; Rogowski F; Jaroszewicz E
Pneumonol Alergol Pol; 1994; 62(5-6):227-32. PubMed ID: 7522725
[TBL] [Abstract][Full Text] [Related]
15. High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients.
Miédougé M; Devys A; Simon M; Rouzaud P; Salama G; Reyre J; Pujazon M; Carles P; Serre G
Tumour Biol; 2001; 22(1):19-26. PubMed ID: 11054023
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.
Niklinski J; Furman M; Chyczewska E; Chyczewski L; Rogowski F; Laudanski J
Eur Respir J; 1995 Feb; 8(2):291-4. PubMed ID: 7538933
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.
Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF
Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024
[TBL] [Abstract][Full Text] [Related]
18. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
19. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels.
Kashiwabara K; Nakamura H; Esaki T
Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677
[TBL] [Abstract][Full Text] [Related]
20. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
